Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)UnknownNCT05819684
What this trial is testing

SHR-4602 in Subjects With Advanced Malignant Solid Tumors

Who this might be right for
Advanced Solid Tumor
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 133
Not applicableNot Yet RecruitingNCT07543250
What this trial is testing

A Real-World Study of Inavolisib in Patients With HR-Positive/HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer

Who this might be right for
Breast Cancer
xuliang 100
Testing effectiveness (Phase 2)Study completedNCT01670877
What this trial is testing

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

Who this might be right for
Breast Neoplasms
Washington University School of Medicine 56
Large-scale testing (Phase 3)Looking for participantsNCT05722886
What this trial is testing

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

Who this might be right for
Haematological MalignancySolid Tumour
Cancer Research UK 825
Early research (Phase 1)Study completedNCT06348888
What this trial is testing

Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy Participants

Who this might be right for
Advanced Non-small Cell Lung CancerEGFR MutationHER2 Mutation+1 more
Bayer 30
Testing effectiveness (Phase 2)UnknownNCT03412383
What this trial is testing

Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

Who this might be right for
Breast CancerHER2 Gene Mutation
Peking Union Medical College 14
Early research (Phase 1)Looking for participantsNCT06625775
What this trial is testing

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Who this might be right for
Solid Tumor, AdultMetastatic Breast CancerAdvanced Breast Cancer+8 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) 392
Early research (Phase 1)Study completedNCT00892736
What this trial is testing

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

Who this might be right for
Basal-Like Breast CarcinomaBRCA1 Mutation CarrierBRCA2 Mutation Carrier+14 more
National Cancer Institute (NCI) 98
Early research (Phase 1)Active Not RecruitingNCT05364073
What this trial is testing

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Metastatic Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung Cancer+3 more
ArriVent BioPharma, Inc. 160
Post-approval studies (Phase 4)Study completedNCT05631795
What this trial is testing

Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 40
Large-scale testing (Phase 3)Looking for participantsNCT05646862
What this trial is testing

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Who this might be right for
Breast Cancer
Hoffmann-La Roche 420
Testing effectiveness (Phase 2)Ended earlyNCT03784599
What this trial is testing

T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
The Netherlands Cancer Institute 28
Testing effectiveness (Phase 2)Study completedNCT03845270
What this trial is testing

Her2-positive Lung Cancer Treated With Dedicated Drug

Who this might be right for
Non Small Cell Lung Cancer MetastaticNon Small Cell Lung Cancer Stage IIIHER2 Gene Mutation
Intergroupe Francophone de Cancerologie Thoracique 46
Large-scale testing (Phase 3)Looking for participantsNCT07195695
What this trial is testing

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

Who this might be right for
Non-small Cell Lung Cancer
Boehringer Ingelheim 400
Testing effectiveness (Phase 2)UnknownNCT05991518
What this trial is testing

IAH0968 in Combination With GC for the Treatment of HER2-Positive Unresectable Advanced/Metastatic Malignant Tumors

Who this might be right for
HER2 Gene Mutation
SUNHO（China）BioPharmaceutical CO., Ltd. 136
Large-scale testing (Phase 3)Looking for participantsNCT06382948
What this trial is testing

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

Who this might be right for
Advanced Breast CancerER-positive Breast CancerHER2-negative Breast Cancer+1 more
MedSIR 300
Testing effectiveness (Phase 2)Study completedNCT02979821
What this trial is testing

Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)

Who this might be right for
HER2 Gene MutationAdenocarcinoma Lung Stage IV
Korean Association for the Study of Targeted Therapy 6
Early research (Phase 1)UnknownNCT04764084
What this trial is testing

Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors

Who this might be right for
HER2-negative Breast CancerGastric AdenocarcinomaCholangiocarcinoma+1 more
Peking University Cancer Hospital & Institute 52
Testing effectiveness (Phase 2)Looking for participantsNCT07405801
What this trial is testing

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 80
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439136
What this trial is testing

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 40
Next Page